Mallinckrodt Lupus Phase 4 Clinical Study for Acthar® Gel (Repository Corticotropin Injection) Completes Enrollment in Difficult-to-Manage Population
(WorldNews Health)

STAINES-UPON-THAMES, United Kingdom, April 23, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed it has completed enrollment in the company`s Phase 4 clinical study assessing the efficacy and safety of Acthar® Gel in Systemic Lupus Erythematosus (lupus, SLE) patients with persistently active disease. This randomized, double-blind, placebo-controlled trial builds on data from a pilot study of Acthar Gel in patients with active SLE. The trial completed enrollment several months ahead of schedule in this underserved population, with a final count of 172 patients. Dr. Anca Askanase, the Director of the Columbia University Lupus...